MS & Immune Disorders
News
Social Networks May Be a Modifiable Risk Factor for MS Progression
Monday, March 04, 2019—Using social network surveys to identify patients with stronger vs weaker social networks (SNs), researchers found that persons with multiple sclerosis (MS) who had significan…
Positive Long-Term Efficacy and Safety of Teriflunomide
Monday, March 04, 2019—Annualized relapse rates (ARR) were significantly lowered for patients treated with 14 mg teriflunomide (Aubagio; Sanofi, Bridgewater, NJ) compared with those treated with pla…
Positive Results for Ublituximab in Phase 2 Clinical Trial
Saturday, March 02, 2019—Patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with ublituximab (TG Therapeutics, New York, NY) (n = 46) had rapid depletion of B cells, reduced …
Early Treatment of Clinically Isolated Syndrome With Interferon ß-1b Shows Benefit Over a 15-Year Period
Saturday, March 02, 2019—Patients with clinically isolated syndrome (CIS) who were treated with interferon ß-1b (IFN) show long term benefits of early treatment (initiation within 2 years of dia…
Partnership Between Community and Academic Healthcare Can Improve Standardization of Imaging Protocols for Multiple Sclerosis
Saturday, March 02, 2019—Guidelines exist for standardized MRI for monitoring disease activity in patients with multiple sclerosis (MS) and enhance quality of care for patients as well as creating the…
Rates of Initiating Disease-Modifying Treatment for Multiple Sclerosis Remain Low
Friday, March 01, 2019—Research suggests that as many as 43% of patients with multiple sclerosis (MS) do not take a disease-modifying treatment (DMT) for the first 2 years of their diagnosis or long…
Comparative Protein Expression Analysis for Precision Diagnosis of Multiple Sclerosis
Friday, March 01, 2019—Gene coexpression with transcriptome analysis, a measure of what genes are actually expressed in an individual, has been used to distinguish patients with relapsing-remitting …
Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Up
Friday, March 01, 2019—After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.…
